MPD: All measures mapped to paradigm code 'dosecoh'

Sort/ Pick	Data set	Procedure / Protocol	Treatment	Phenotype Measure / Variable (click to view)	Panel	No. of Strains	Sex	Age	Sample Size (Avg)	Year
Attie2:102	Attie2	hormone quantification	high-fat high-sucrose diet	ex vivo insulin secretion after diet in response to glucose [ng/mL] INS_GLU 110719 3.3 mM 8.3 mM 16.7 mM	DO population		both	19-26wks	N=242	2018

Attie2:118	Attie2	hormone quantification	high-fat high-sucrose diet	ex vivo insulin secretion after diet in response to glucose, expressed as a percentage of total insulin per mouse [%] INS_pct_GLU 110735 3.3 mM 8.3 mM 16.7 mM	DO population		both	19-26wks	N=241	2018

Attie2:125	Attie2	hormone quantification	high-fat high-sucrose diet	ex vivo insulin secretion after diet in response to glucose (geometric mean) [ng/mL] INS_gm_GLU 110742 3.3 mM 8.3 mM 16.7 mM	DO population		both	19-26wks	N=242	2018

Boon1:1	Boon1	body weight	(none)	body weight, pre-infection [g] bw_start 46901 dosage group: low medium high	inbred	23	f	6-9wks	N=11	2011

Boon1:11	Boon1	body weight	influenza A (H5N1) virus	change in body weight, post-infection [%] bw_change 46911 dosage group: low medium high	inbred	23	f	6-9wks	N=11	2011

Boon1:21	Boon1	health assessment	influenza A (H5N1) virus	survival (days to death, max 30) [d] survival 46921 dosage group: low medium high	inbred	23	f	6-9wks	N=11	2011

Boon1:31	Boon1	health assessment	influenza A (H5N1) virus	susceptibility to viral infection (0=susceptible, 1=resistant) [designation] resistance 46931 dosage group: low medium high	inbred	23	f	6-9wks	N=11	2011

Crabbe2:1	Crabbe2	drug and metabolite quantification	diazepam	brain diazepam and metabolite concentration, 30 min post-injection [ng/g] brain_DZ 15501 8 mg/kg 16 mg/kg	inbred	15	m	6-7wks	N=8	1998

Crabbe3:10	Crabbe3	rotarod	ethanol	latency to fall, fixed speed 3 rpm rotarod [s] FS_3rpm_EtOH 15810 dose (g/kg): 1 2 3	inbred	9	both	9-17wks	N=4	2003

Crabbe3:15	Crabbe3	rotarod	ethanol	latency to fall, fixed speed 6 rpm rotarod [s] FS_6rpm_EtOH 15815 dose (g/kg) 1 2 3	inbred	9	both	9-17wks	N=3	2003

Crabbe3:20	Crabbe3	rotarod	ethanol	latency to fall, fixed speed 10 rpm rotarod [s] FS_10rpm_EtOH 15820 dose (g/kg): 1 2 3	inbred	9	both	9-17wks	N=3	2003

Gould2:1	Gould2	drug and metabolite quantification	nicotine	plasma nicotine [ng/mL] nicotine 47101 acute 0.09mg dose chronic 6.3mg dose	inbred	8	m	8-12wks	N=10	2011

Gould2:3	Gould2	drug and metabolite quantification	nicotine	plasma cotinine [ng/mL] cotinine 47105 acute 0.09mg dose chronic 6.3mg dose	inbred	8	m	8-12wks	N=10	2011

Parker1:1	Parker1	assisted reproduction	(none)	mean number of oocytes per female following treatment [n] oocyte_num 62901 2.5 IU eCG 5 IU eCG 5 + 5 IU eCG	inbred	6	f	3-6wks	N=18	2011

Parker1:4	Parker1	assisted reproduction	(none)	mean number of fertilized oocytes per female following treatment [n] oocyte_fert_num 62904 2.5 IU eCG 5 IU eCG 5 + 5 IU eCG	inbred	6	f	3-6wks	N=18	2011

Parker1:7	Parker1	assisted reproduction	(none)	percentage of oocytes that are fertilized per female following treatment [%] oocyte_fert_pct 62907 2.5 IU eCG 5 IU eCG 5 + 5 IU eCG	inbred	6	f	3-6wks	N=18	2011

Schughart3:81	Schughart3	health assessment	influenza A (H3N2) virus	survival, post-infection [d] day_survival 57181 10 FFU group 2000 FFU group 200000 FFU group	inbred w/CC8	8	both	7-13wks	N=11	2013

Schughart3:91	Schughart3	health assessment	influenza A (H3N2) virus	susceptibility to viral infection (0=resistant, 1=susceptible), mortality rate [score] status_day_survival 57191 10 FFU group 2000 FFU group 200000 FFU group	inbred w/CC8	8	both	7-13wks	N=11	2013

Threadgill2:2	Threadgill2	metabolic panel	acetaminophen	alanine transaminase (serum ALT) [IU/L] ALT 39602 50 mg/kg 300 mg/kg	inbred	5	m	6-8wks	N=5	2005

Attie2

hormone quantification

high-fat high-sucrose diet

ex vivo insulin secretion after diet in response to glucose [ng/mL] INS_GLU 110719 3.3 mM 8.3 mM 16.7 mM

DO population

both

19-26wks

N=242

2018

Attie2

hormone quantification

high-fat high-sucrose diet

ex vivo insulin secretion after diet in response to glucose, expressed as a percentage of total insulin per mouse [%] INS_pct_GLU 110735 3.3 mM 8.3 mM 16.7 mM

DO population

both

19-26wks

N=241

2018

Attie2

hormone quantification

high-fat high-sucrose diet

ex vivo insulin secretion after diet in response to glucose (geometric mean) [ng/mL] INS_gm_GLU 110742 3.3 mM 8.3 mM 16.7 mM

DO population

both

19-26wks

N=242

2018

Boon1

body weight

(none)

body weight, pre-infection [g] bw_start 46901 dosage group: low medium high

inbred

23

f

6-9wks

N=11

2011

Boon1

body weight

influenza A (H5N1) virus

change in body weight, post-infection [%] bw_change 46911 dosage group: low medium high

inbred

23

f

6-9wks

N=11

2011

Boon1

health assessment

influenza A (H5N1) virus

survival (days to death, max 30) [d] survival 46921 dosage group: low medium high

inbred

23

f

6-9wks

N=11

2011

Boon1

health assessment

influenza A (H5N1) virus

susceptibility to viral infection (0=susceptible, 1=resistant) [designation] resistance 46931 dosage group: low medium high

inbred

23

f

6-9wks

N=11

2011

Crabbe2

drug and metabolite quantification

diazepam

brain diazepam and metabolite concentration, 30 min post-injection [ng/g] brain_DZ 15501 8 mg/kg 16 mg/kg

inbred

15

m

6-7wks

N=8

1998

Crabbe3

rotarod

ethanol

latency to fall, fixed speed 3 rpm rotarod [s] FS_3rpm_EtOH 15810 dose (g/kg): 1 2 3

inbred

9

both

9-17wks

N=4

2003

Crabbe3

rotarod

ethanol

latency to fall, fixed speed 6 rpm rotarod [s] FS_6rpm_EtOH 15815 dose (g/kg) 1 2 3

inbred

9

both

9-17wks

N=3

2003

Crabbe3

rotarod

ethanol

latency to fall, fixed speed 10 rpm rotarod [s] FS_10rpm_EtOH 15820 dose (g/kg): 1 2 3

inbred

9

both

9-17wks

N=3

2003

Gould2

drug and metabolite quantification

nicotine

plasma nicotine [ng/mL] nicotine 47101 acute 0.09mg dose chronic 6.3mg dose

inbred

8

m

8-12wks

N=10

2011

Gould2

drug and metabolite quantification

nicotine

plasma cotinine [ng/mL] cotinine 47105 acute 0.09mg dose chronic 6.3mg dose

inbred

8

m

8-12wks

N=10

2011

Parker1

assisted reproduction

(none)

mean number of oocytes per female following treatment [n] oocyte_num 62901 2.5 IU eCG 5 IU eCG 5 + 5 IU eCG

inbred

6

f

3-6wks

N=18

2011

Parker1

assisted reproduction

(none)

mean number of fertilized oocytes per female following treatment [n] oocyte_fert_num 62904 2.5 IU eCG 5 IU eCG 5 + 5 IU eCG

inbred

6

f

3-6wks

N=18

2011

Parker1

assisted reproduction

(none)

percentage of oocytes that are fertilized per female following treatment [%] oocyte_fert_pct 62907 2.5 IU eCG 5 IU eCG 5 + 5 IU eCG

inbred

6

f

3-6wks

N=18

2011

Schughart3

health assessment

influenza A (H3N2) virus

survival, post-infection [d] day_survival 57181 10 FFU group 2000 FFU group 200000 FFU group

inbred w/CC8

8

both

7-13wks

N=11

2013

Schughart3

health assessment

influenza A (H3N2) virus

susceptibility to viral infection (0=resistant, 1=susceptible), mortality rate [score] status_day_survival 57191 10 FFU group 2000 FFU group 200000 FFU group

inbred w/CC8

8

both

7-13wks

N=11

2013

Threadgill2

metabolic panel

acetaminophen

alanine transaminase (serum ALT) [IU/L] ALT 39602 50 mg/kg 300 mg/kg

inbred

5

m

6-8wks

N=5

2005

Study designs: all MPD measure sets of study design type dosecoh

Filter Table Results